Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market to Reach USD 64.09 Billion by 2033 at 35.3% CAGR; North America Leads with 41.2% Share - Key Players: Pfizer Inc., Ionis Pharmaceuticals

The global transthyretin amyloid cardiomyopathy (ATTR-CM) market reached USD 5.85 billion in 2025 and is expected to reach USD 64.09 billion by 2033, growing at a CAGR of 35.3% during the forecast period from 2026 to 2033. The market is witnessing rapid growth driven by the increasing prevalence of rare cardiac disorders, rising awareness and diagnosis of ATTR-CM, and growing demand for targeted and disease-modifying therapies. Advancements in diagnostic techniques and improved screening practices are further accelerating early detection and treatment adoption.

Market growth is strongly supported by significant advancements in therapeutic development, including transthyretin stabilizers, gene-silencing therapies, and emerging gene-editing approaches. Pharmaceutical companies are actively investing in clinical trials and expanding their pipelines to address unmet medical needs in ATTR-CM treatment. At the same time, increasing regulatory support, including expedited approvals and orphan drug designations, along with expanding market access initiatives, is facilitating faster commercialization and broader patient reach.

ATTR-CM therapies play a critical role in slowing disease progression, improving cardiac function, and enhancing patient survival rates. Continuous innovation in precision medicine and targeted treatment strategies is transforming disease management. Furthermore, growing collaborations between pharmaceutical companies, research institutions, and healthcare providers are strengthening treatment accessibility and care delivery. With strong momentum in rare disease research, technological advancements, and regulatory support, the ATTR-CM market is poised for exponential and transformative growth.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market?sai-v

Key Developments

September 2025: Rising awareness and improved diagnosis of transthyretin amyloid cardiomyopathy significantly boosted demand for early diagnosis, supported by increasing use of non-invasive imaging and biomarker-based detection methods.

October 2025: Growing adoption of targeted therapies, particularly transthyretin stabilizers such as tafamidis, improved survival outcomes and became the standard of care for ATTR-CM patients.

November 2025: Rapid advancements in RNA therapies, including gene-silencing drugs like vutrisiran and eplontersen, expanded treatment options by reducing transthyretin protein production and slowing disease progression.

December 2025: Leading pharmaceutical companies increased investments in pipeline innovation, focusing on next-generation therapies such as monoclonal antibodies, gene editing approaches, and combination treatments targeting amyloid deposits.

January 2026: Positive clinical trial outcomes for next-generation drugs such as acoramidis demonstrated significant improvements in survival and cardiovascular outcomes, strengthening confidence in emerging therapies.

February 2026: Intensifying market competition and regulatory advancements accelerated adoption of novel treatments, with new drug approvals and expanding therapeutic options driving market growth and improving patient access.

The market is rapidly evolving toward targeted, disease-modifying, and potentially curative therapies, where innovations in RNA-based treatments, gene editing, and advanced diagnostics are transforming disease management and significantly improving outcomes for patients with ATTR-CM.

Key Players

Pfizer Inc. | Ionis Pharmaceuticals, Inc. | Others

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=transthyretin-amyloid-cardiomyopathy-market?sai-v

Market Drivers

Rising prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM), particularly among the aging population, is significantly driving demand for effective diagnostics and therapies.

Increasing awareness and improved non-invasive diagnostic techniques such as nuclear imaging and genetic testing are enabling earlier detection and expanding the patient pool.

Growing adoption of targeted therapies including transthyretin stabilizers and RNAi-based treatments is accelerating market growth due to improved clinical outcomes.

Rising investments in rare disease research and orphan drug development are boosting innovation and expanding treatment pipelines.

High unmet medical need and previously limited treatment options are encouraging rapid development and adoption of novel therapeutics.

Increasing geriatric population, which is more susceptible to wild-type ATTR-CM, is further supporting market expansion.

Expansion of specialty cardiac care centers and improved clinical awareness among cardiologists are enhancing diagnosis and treatment rates.

Industry Developments

Rapid advancement of RNA interference (RNAi) therapies and gene-silencing technologies offering disease-modifying treatment approaches.

Increasing development of next-generation transthyretin stabilizers such as acoramidis improving efficacy and patient outcomes.

Growing number of regulatory approvals for novel therapies expanding treatment options for both hereditary and wild-type ATTR-CM.

Expansion of clinical trials and pipeline therapies, including gene-editing approaches, indicating potential for long-term or curative treatments.

Rising focus on combination therapies targeting multiple disease mechanisms to improve survival and quality of life.

Increasing use of advanced imaging and diagnostic pathways to support early and accurate disease identification.

Strategic collaborations between pharmaceutical companies and research institutions to accelerate innovation and commercialization.

Regional Insights

North America 41.2% share: "Leads the market due to strong healthcare infrastructure, early adoption of advanced therapies, high disease awareness, and robust clinical research activity."

Europe 28.0% share: "Growth supported by established healthcare systems, increasing adoption of novel therapies, and strong regulatory support for rare diseases."

Asia Pacific 18.6% share: "Fastest-growing region driven by rising healthcare expenditure, improving diagnostic capabilities, and increasing awareness in countries like China and Japan."

Latin America 6.5% share: "Emerging growth supported by improving access to diagnostics, expanding healthcare infrastructure, and rising awareness of cardiac amyloidosis."

Middle East & Africa 5.7% share: "Gradual growth driven by increasing healthcare investments and improving recognition of rare cardiovascular diseases."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market?sai-v

Key Segments

➥ By Type
Familial (Hereditary) ATTR-CM: Represents a significant segment, driven by genetic mutations leading to transthyretin amyloid deposition and increasing diagnosis through genetic screening.

Wild-type ATTR-CM: Represents the dominant segment, supported by its higher prevalence among the aging population and improved awareness of the condition.

➥ By Drug Type
Transthyretin Stabilizers: Represent the dominant segment, driven by their ability to prevent misfolding of transthyretin protein and slow disease progression.

RNAi Therapy: Represents a rapidly growing segment, supported by advancements in gene-silencing technologies targeting transthyretin production.

Others: Represent a niche segment, including emerging therapies such as antisense oligonucleotides and combination treatments.

➥ By Distribution Channel
Hospital Pharmacies: Represent the dominant segment, driven by administration of specialized therapies and access to advanced treatment facilities.

Retail Pharmacies: Represent a significant segment, supported by availability of maintenance medications and patient accessibility.

Online Pharmacies: Represent a growing segment, fueled by increasing adoption of digital healthcare platforms and convenience of home delivery.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.